443 related articles for article (PubMed ID: 19345042)
21. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
Abdel-Salam HA
Mycoses; 2005 Sep; 48(5):327-32. PubMed ID: 16115103
[TBL] [Abstract][Full Text] [Related]
22. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
23. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
25. Enhanced diallyl trisulfide has in vitro synergy with amphotericin B against Cryptococcus neoformans.
Shen J; Davis LE; Wallace JM; Cai Y; Lawson LD
Planta Med; 1996 Oct; 62(5):415-8. PubMed ID: 8923805
[TBL] [Abstract][Full Text] [Related]
26. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
Tapia C; León E; Palavecino E
Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
[TBL] [Abstract][Full Text] [Related]
27. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
28. Comparison of different in vitro tests to detect Cryptococcus neoformans not susceptible to amphotericin B.
Córdoba S; Vivot W; Szusz W; Isla G; Davel G
Mycopathologia; 2015 Jun; 179(5-6):359-71. PubMed ID: 25700663
[TBL] [Abstract][Full Text] [Related]
29. Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela.
Calvo BM; Colombo AL; Fischman O; Santiago A; Thompson L; Lazera M; Telles F; Fukushima K; Nishimura K; Tanaka R; Myiajy M; Moretti-Branchini ML
J Clin Microbiol; 2001 Jun; 39(6):2348-50. PubMed ID: 11376089
[TBL] [Abstract][Full Text] [Related]
30. 5-Fluorocytosine resistance in clinical isolates of Cryptococcus neoformans.
Chin CS; Cheong YM; Wong YH
Med J Malaysia; 1989 Sep; 44(3):194-8. PubMed ID: 2696871
[TBL] [Abstract][Full Text] [Related]
31. Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya.
Bii CC; Makimura K; Abe S; Taguchi H; Mugasia OM; Revathi G; Wamae NC; Kamiya S
Mycoses; 2007 Jan; 50(1):25-30. PubMed ID: 17302744
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis.
Wang H; Xu K; Liu L; Tan JP; Chen Y; Li Y; Fan W; Wei Z; Sheng J; Yang YY; Li L
Biomaterials; 2010 Apr; 31(10):2874-81. PubMed ID: 20044131
[TBL] [Abstract][Full Text] [Related]
33. In vitro susceptibility testing of amphotericin B for Cryptococcus neoformans variety grubii AFLP1/VNI and Cryptococcus gattii AFLP6/VGII by CLSI and flow cytometry.
Morales BP; Trilles L; Bertho ÁL; Junior IN; de Oliveira Rde V; Wanke B; Lazéra Mdos S
Mycoses; 2015 May; 58(5):273-9. PubMed ID: 25756839
[TBL] [Abstract][Full Text] [Related]
34. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
Tay ST; Tanty Haryanty T; Ng KP; Rohani MY; Hamimah H
Mycoses; 2006 Jul; 49(4):324-30. PubMed ID: 16784448
[TBL] [Abstract][Full Text] [Related]
35. In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction.
Rossato L; Loreto ÉS; Venturini TP; Azevedo MI; Weiblen C; Botton SA; Santurio JM; Alves SH
Med Mycol; 2015 Nov; 53(8):885-9. PubMed ID: 26333356
[TBL] [Abstract][Full Text] [Related]
36. Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.
Aller AI; Claro R; Castro C; Serrano C; Colom MF; Martín-Mazuelos E
Chemotherapy; 2007; 53(4):300-5. PubMed ID: 17496416
[TBL] [Abstract][Full Text] [Related]
37. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
38. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
39. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
40. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.
Schwarz P; Janbon G; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2007 Jan; 51(1):383-5. PubMed ID: 17043122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
